Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04586075 · ClinicalTrials.gov registry record
UW Undiagnosed Genetic Diseases Program
A clinical trial of Genetic Disease and Rare Diseases, sponsored by University of Wisconsin, Madison.
- Recruiting
- Registry status
- 500
- Enrollment target
- 1
- Study location
NCT04586075: Recruiting study of Genetic Disease and Rare Diseases, sponsored by University of Wisconsin, Madison.
NCT04586075 is a study of Genetic Disease and Rare Diseases that is actively recruiting participants, run by University of Wisconsin, Madison. The registered enrollment target is 500 participants, below the 2,545-participant average among 30 other Genetic Disease trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04586075, a study of Genetic Disease and Rare Diseases, is actively recruiting participants, sponsored by University of Wisconsin, Madison.
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary purpose of this study is to discover new disease genes for rare Mendelian disorders and its secondary purpose include diagnosing people with rare genetic disorders that have not been previously diagnosed through conventional clinical means, learning more about the pathobiology of genetic disorders, and developing novel diagnostic technologies and analytics. 500 participants with undiagnosed and suspected genetic disorders will be recruited.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Trio Whole Genome Sequencing and Participant-Specific Research
Study Locations (1)
Wisconsin
- University of Wisconsin School of Medicine and Public Health - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2021-07-16 |
| Est. Completion | 2030-10 |
What NCT04586075 shows while recruiting
NCT04586075 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, below the 2,545-participant average among 30 other Genetic Disease trials with a reported enrollment target (80% lower).
The record links to 3 conditions, with Genetic Disease appearing as the primary indexed condition, and to 1 intervention - of which Trio Whole Genome Sequencing and Participant-Specific Research is the first listed.
NCT04586075 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT04586075 about?
NCT04586075 is a clinical study titled "UW Undiagnosed Genetic Diseases Program". The primary purpose of this study is to discover new disease genes for rare Mendelian disorders and its secondary purpose include diagnosing people with rare genetic disorders that have not been previously diagnosed through conventional clinical means, learning more about the pathobiology of genetic...
What is the current status of trial NCT04586075?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2021-07-16. Estimated completion is 2030-10.
What conditions does trial NCT04586075 study?
This clinical trial studies the following conditions: Genetic Disease, Rare Diseases, Undiagnosed Disease.
What interventions are being tested in trial NCT04586075?
The interventions under investigation include: Trio Whole Genome Sequencing and Participant-Specific Research (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04586075?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04586075 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Genetic Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04586075's enrollment target sits among peer trials
500 10th of 30 higher than 19 of 30 other Genetic Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Genetic Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
An Adaptive Clinical Trial of BeginNGS Newborn Screening for Hundreds of Genetic Diseases by Genome Sequencing
RECRUITING · NA
-
Delineating the Molecular Spectrum and the Clinical, Imaging and Neuronal Phenotype of Chopra-Amiel-Gordon Syndrome
RECRUITING
-
Rett Syndrome Registry
RECRUITING
-
Natural History Study of Patients with HPDL Mutations
RECRUITING
-
Diagnostic Odyssey: Whole Genome Sequencing (WGS)
RECRUITING
-
Clinical and Genetic Evaluation of Individuals With Undiagnosed Disorders Through the Undiagnosed Diseases Network
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI